{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:22:07Z","timestamp":1790702527186,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11886-018-1004-9","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T22:35:06Z","timestamp":1529534106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?"],"prefix":"10.1007","volume":"20","author":[{"given":"I.","family":"Karalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"issue":"2","key":"1004_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434\u201344.","journal-title":"Diabetes Care"},{"issue":"6797","key":"1004_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","volume":"303","author":"Z Chen","year":"1991","unstructured":"Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303(6797):276\u201382.","journal-title":"BMJ"},{"issue":"1","key":"1004_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/CIR.0b013e3182456d46","volume":"125","author":"VL Roger","year":"2012","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188\u201397. https:\/\/doi.org\/10.1161\/CIR.0b013e3182456d46 .","journal-title":"Circulation"},{"issue":"7897","key":"1004_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","volume":"1","author":"GJ Miller","year":"1975","unstructured":"Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1(7897):16\u20139.","journal-title":"Lancet"},{"issue":"6","key":"1004_CR5","first-page":"941","volume":"88","author":"CJ Glueck","year":"1976","unstructured":"Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med. 1976;88(6):941\u201357.","journal-title":"J Lab Clin Med"},{"issue":"5","key":"1004_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707\u201314.","journal-title":"Am J Med"},{"issue":"20","key":"1004_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237\u201345. https:\/\/doi.org\/10.1056\/NEJM198711123172001.","journal-title":"N Engl J Med"},{"issue":"5","key":"1004_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/ATVBAHA.116.307024","volume":"36","author":"RS Rosenson","year":"2016","unstructured":"Rosenson RS. The high-density lipoprotein puzzle: why classic epidemiology, genetic epidemiology, and clinical trials conflict? Arterioscler Thromb Vasc Biol. 2016;36(5):777\u201382. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307024 .","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1004_CR9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/CIRCOUTCOMES.111.000014","volume":"6","author":"I Karalis","year":"2013","unstructured":"Karalis I, Rensen PCN, Jukema JW. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ Cardiovasc Qual Outcomes. 2013;6(3):360\u20136. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.111.000014 .","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"13","key":"1004_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Group HPSTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of Anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1706444.","journal-title":"N Engl J Med"},{"issue":"1","key":"1004_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1743-7075-9-25","volume":"9","author":"W Annema","year":"2012","unstructured":"Annema W, Tietge UJ. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond). 2012;9(1):25. https:\/\/doi.org\/10.1186\/1743-7075-9-25 .","journal-title":"Nutr Metab (Lond)"},{"issue":"4","key":"1004_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","volume":"30","author":"M Llera-Moya de la","year":"2010","unstructured":"de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30(4):796\u2013801. https:\/\/doi.org\/10.1161\/ATVBAHA.109.199158 .","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"1004_CR13","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1409065.","journal-title":"N Engl J Med"},{"issue":"2","key":"1004_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1001689.","journal-title":"N Engl J Med"},{"issue":"10","key":"1004_CR15","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1161\/01.ATV.0000092328.66882.F5","volume":"23","author":"RE Moore","year":"2003","unstructured":"Moore RE, M-a K, Kitajima K, Secreto A, Millar JS, Pratico D, et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol. 2003;23(10):1914\u201320. https:\/\/doi.org\/10.1161\/01.ATV.0000092328.66882.F5 .","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1004_CR16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0022-2275(20)33893-1","volume":"39","author":"E Voyiaziakis","year":"1998","unstructured":"Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39(2):313\u201321.","journal-title":"J Lipid Res"},{"issue":"7","key":"1004_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jacc.2004.06.070","volume":"44","author":"GK Hovingh","year":"2004","unstructured":"Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JHM, Petersen W, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44(7):1429\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2004.06.070 .","journal-title":"J Am Coll Cardiol"},{"key":"1004_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/978-3-319-09665-0_21","volume":"224","author":"RM Stoekenbroek","year":"2015","unstructured":"\u2022\u2022 Stoekenbroek RM, Stroes ES, Hovingh GK. ApoA-I mimetics. Handb Exp Pharmacol. 2015;224:631\u201348. https:\/\/doi.org\/10.1007\/978-3-319-09665-0_21 . This review article nicely summarizes recent studies with HDL mimetic agents.","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"1004_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","volume":"49","author":"LT Bloedon","year":"2008","unstructured":"Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008;49(6):1344\u201352. https:\/\/doi.org\/10.1194\/jlr.P800003-JLR200 .","journal-title":"J Lipid Res"},{"issue":"2","key":"1004_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1194\/jlr.M011098","volume":"52","author":"CE Watson","year":"2011","unstructured":"Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2011;52(2):361\u201373. https:\/\/doi.org\/10.1194\/jlr.M011098 .","journal-title":"J Lipid Res"},{"issue":"4","key":"1004_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1194\/jlr.M033555","volume":"54","author":"A Chattopadhyay","year":"2013","unstructured":"Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res. 2013;54(4):995\u20131010. https:\/\/doi.org\/10.1194\/jlr.M033555 .","journal-title":"J Lipid Res"},{"issue":"2","key":"1004_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1124\/jpet.110.167890","volume":"334","author":"MJA Amar","year":"2010","unstructured":"Amar MJA, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334(2):634\u201341. https:\/\/doi.org\/10.1124\/jpet.110.167890 .","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1004_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/ATVBAHA.109.200196","volume":"30","author":"F Tabet","year":"2010","unstructured":"Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, et al. The 5A apolipoprotein a-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol. 2010;30(2):246\u201352. https:\/\/doi.org\/10.1161\/ATVBAHA.109.200196 .","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1004_CR24","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1194\/jlr.M003665","volume":"51","author":"JK Bielicki","year":"2010","unstructured":"Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res. 2010;51(6):1496\u2013503. https:\/\/doi.org\/10.1194\/jlr.M003665 .","journal-title":"J Lipid Res"},{"issue":"2","key":"1004_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2011.05.029","volume":"218","author":"A Iwata","year":"2011","unstructured":"Iwata A, Miura S-i, Zhang B, Imaizumi S, Uehara Y, Shiomi M, et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide\/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis. 2011;218(2):300\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.05.029 .","journal-title":"Atherosclerosis"},{"issue":"4","key":"1004_CR26","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1172\/JCI114558","volume":"85","author":"JJ Badimon","year":"1990","unstructured":"Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85(4):1234\u201341. https:\/\/doi.org\/10.1172\/JCI114558.","journal-title":"J Clin Invest"},{"issue":"11","key":"1004_CR27","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/01.ATV.15.11.1882","volume":"15","author":"A Miyazaki","year":"1995","unstructured":"Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15(11):1882\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"1004_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","volume":"103","author":"CR Sirtori","year":"2001","unstructured":"Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001;103(15):1949\u201354.","journal-title":"Circulation"},{"issue":"1\u20133","key":"1004_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0021-9150(85)90063-2","volume":"58","author":"G Franceschini","year":"1985","unstructured":"Franceschini G, Sirtori CR, Bosisio E, Gualandri V, Orsini GB, Mogavero AM, et al. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 1985;58(1\u20133):159\u201374.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1004_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2011.10.006","volume":"220","author":"B Ibanez","year":"2012","unstructured":"Ibanez B, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis. 2012;220(1):72\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.10.006 .","journal-title":"Atherosclerosis"},{"issue":"17","key":"1004_CR31","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292\u2013300. https:\/\/doi.org\/10.1001\/jama.290.17.2292 .","journal-title":"JAMA"},{"issue":"4","key":"1004_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10557-017-6746-x","volume":"31","author":"JAA Reijers","year":"2017","unstructured":"Reijers JAA, Kallend DG, Malone KE, Jukema JW, Wijngaard PLJ, Burggraaf J, et al. MDCO-216 does not induce adverse Immunostimulation, in contrast to its predecessor ETC-216. Cardiovasc Drugs Ther. 2017;31(4):381\u20139. https:\/\/doi.org\/10.1007\/s10557-017-6746-x .","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"1004_CR33","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"J-C Tardif","year":"2007","unstructured":"Tardif J-C. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosisa randomized controlled trial. JAMA. 2007;297(15):1675\u201382. https:\/\/doi.org\/10.1001\/jama.297.15.jpc70004 .","journal-title":"JAMA"},{"issue":"3","key":"1004_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jcph.194","volume":"54","author":"R Easton","year":"2013","unstructured":"Easton R, Gille A, D'Andrea D, Davis R, Wright Samuel D, Shear C. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol. 2013;54(3):301\u201310. https:\/\/doi.org\/10.1002\/jcph.194 .","journal-title":"J Clin Pharmacol"},{"issue":"24","key":"1004_CR35","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","volume":"134","author":"C Michael Gibson","year":"2016","unstructured":"Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I). Circulation. 2016;134(24):1918\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025687 .","journal-title":"Circulation"},{"issue":"46","key":"1004_CR36","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"J-C Tardif","year":"2014","unstructured":"Tardif J-C, Ballantyne CM, Barter P, Dasseux J-L, Fayad ZA, Guertin M-C, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35(46):3277\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehu171 .","journal-title":"Eur Heart J"},{"issue":"3","key":"1004_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.21037\/cdt.2017.02.01","volume":"7","author":"Y Kataoka","year":"2017","unstructured":"Kataoka Y, Andrews J, Duong M, Nguyen T, Schwarz N, Fendler J, et al. Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovasc Diagn Ther. 2017;7(3):252\u201363. https:\/\/doi.org\/10.21037\/cdt.2017.02.01 .","journal-title":"Cardiovasc Diagn Ther"},{"issue":"9","key":"1004_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137584","volume":"10","author":"C Tardy","year":"2015","unstructured":"Tardy C, Goffinet M, Boubekeur N, Cholez G, Ackermann R, Sy G, et al. HDL and CER-001 inverse-dose dependent inhibition of atherosclerotic plaque formation in apoE\u2212\/\u2212 mice: evidence of ABCA1 down-regulation. PLoS One. 2015;10(9):e0137584. https:\/\/doi.org\/10.1371\/journal.pone.0137584 .","journal-title":"PLoS One"},{"issue":"1","key":"1004_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.21037\/cdt.2017.01.01","volume":"7","author":"J Andrews","year":"2017","unstructured":"Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJP, et al. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther. 2017;7(1):45\u201351. https:\/\/doi.org\/10.21037\/cdt.2017.01.01 .","journal-title":"Cardiovasc Diagn Ther"},{"issue":"3","key":"1004_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1194\/jlr.M055665","volume":"56","author":"RS Kootte","year":"2015","unstructured":"Kootte RS, Smits LP, van der Valk FM, Dasseux J-L, Keyserling CH, Barbaras R, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015;56(3):703\u201312. https:\/\/doi.org\/10.1194\/jlr.M055665 .","journal-title":"J Lipid Res"},{"issue":"5","key":"1004_CR41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.ahj.2015.01.008","volume":"169","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Smits LP, Stefanutti C, Soran H, Kwok S, de Graaf J, et al. The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. Am Heart J. 2015;169(5):736\u201342.e1. https:\/\/doi.org\/10.1016\/j.ahj.2015.01.008 .","journal-title":"Am Heart J"},{"issue":"21","key":"1004_CR42","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322. https:\/\/doi.org\/10.1056\/NEJMoa0706628.","journal-title":"N Engl J Med"},{"issue":"22","key":"1004_CR43","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1206797.","journal-title":"N Engl J Med"},{"issue":"1","key":"1004_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","volume":"113","author":"AM Gotto","year":"2014","unstructured":"Gotto AM, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113(1):76\u201383. https:\/\/doi.org\/10.1016\/j.amjcard.2013.08.041 .","journal-title":"Am J Cardiol"},{"key":"1004_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00490","volume":"5","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Dragoljevic D, Tall AR. Cholesterol efflux pathways regulate myelopoiesis: a potential link to altered macrophage function in atherosclerosis. Front Immunol. 2014;5:490. https:\/\/doi.org\/10.3389\/fimmu.2014.00490 .","journal-title":"Front Immunol"},{"issue":"9","key":"1004_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.jacc.2015.12.048","volume":"67","author":"P Libby","year":"2016","unstructured":"\u2022\u2022 Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded \"cardiovascular continuum\". J Am Coll Cardiol. 2016;67(9):1091\u2013103. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.048 . In this article, current views in the pathophysiology of atherosclerosis are discussed.","journal-title":"J Am Coll Cardiol"},{"issue":"6278","key":"1004_CR47","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"\u2022 Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science (New York, NY). 2016;351(6278):1166\u201371. https:\/\/doi.org\/10.1126\/science.aad3517 . Recent article suggesting that despite the number of negative trials, the reverse cholesterol transport pathway should not be excluded as a valid therapeutic option.","journal-title":"Science (New York, NY)"},{"issue":"20","key":"1004_CR48","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1161\/hc4501.098952","volume":"104","author":"JX Rong","year":"2001","unstructured":"Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104(20):2447\u201352.","journal-title":"Circulation"},{"issue":"21","key":"1004_CR49","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","volume":"55","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399\u2013407. https:\/\/doi.org\/10.1016\/j.jacc.2010.02.026 .","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-018-1004-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-018-1004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-018-1004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T22:23:10Z","timestamp":1661466190000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-018-1004-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1007\/s11886-018-1004-9","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s12595-026-00609-4","asserted-by":"object"}]},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"21 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"J.W. Jukema\/his department has received research grants from and\/or was speaker (with or without lecture fees) on among others (CME accredited) meetings sponsored by The Medicine Company, the Netherlands Heart Foundation, CardioVascular Research of the Netherlands (CVON), the Interuniversity Cardiology Institute of the Netherlands, and the European Community Framework KP7 Program.I. Karalis declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"66"}}